Pharmacological inhibition of diacylglycerol acyltransferase 1 reduces body weight and modulates gut peptide release - Potential insight into mechanism of action

Obesity

Volumn 21, Issue 7, 2013, Pages 1406-1415

  Liu, Jinqi ^a   Gorski, Judith N ^a   Gold, Stephen J ^a   Chen, Dunlu ^a   Chen, Shirley ^a   Forrest, Gail ^a   Itoh, Yoshiki ^b   Marsh, Donald J ^a   McLaren, David G ^a   Shen, Zhu ^a   Sonatore, Lisa ^a   Carballo Jane, Ester ^a   Craw, Stephanie ^a   Guan, Xiaoming ^c   Karanam, Bindhu ^a   Sakaki, Junichi ^d   Szeto, Daphne ^a   Tong, Xinchun ^a   Xiao, Jianying ^a   Yoshimoto, Ryo ^e   Yu, Hong ^a   Roddy, Thomas P ^a   Balkovec, James ^a   Pinto, Shirly ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

^b Sato Pharmaceuticals Co Ltd   (Japan)

^c GLAXOSMITHKLINE   (China)

^d Mochida Pharmaceuticals Co Ltd   (Japan)

^e SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE INHIBITOR; CARBON 13; DIACYLGLYCEROL ACYLTRANSFERASE 1; DIACYLGLYCEROL ACYLTRANSFERASE 1 INHIBITOR; FATTY ACID; INCRETIN; PHOSPHATIDYLCHOLINE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOCHEMISTRY; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; ENTEROENDOCRINE CELL; ENZYME INHIBITION; HOMEOSTASIS; HORMONE RELEASE; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; ISOTOPE LABELING; LIPID METABOLISM; LIPOGENESIS; MALE; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PROVOCATION TEST; WEIGHT REDUCTION;

CANIS FAMILIARIS; MUS;

EID: 84881555506     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20193     Document Type: Article

References (32)

1. Friedman JM,. Obesity of the new millennium. Nature 2000; 404: 632-634.
2. Spiegelman BM, Flier JS,. Adipogenesis and obesity: rounding out the big picture. Cell 1996; 87: 377-389.
3. Flier JS,. Obesity wars: molecular progress confronts an expanding epidemic. Cell 2004; 116: 337-350.
4. Capeau J,. Insulin resistance and steatosis in humans. Diabetes Metab 2008; 34: 649-657.
5. Kennedy EP,. Metabolism of lipids. Annu Rev Biochem 1957; 26: 119-148.
6. Kayden HJ, Senior JR, Mattson FH,. The monoglyceride pathway of fat absorption in man. J Clin Invest 1967; 46: 1695-1703.
7. Cases S, Smith SJ, Zheng YW, et al. Identification of a gene encoding an acyl CoA: diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. Proc Natl Acad Sci USA 1998; 95: 13018-13023.
8. Cases S, Stone SJ, Zhou P, et al. Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members. J Biol Chem 2001; 276: 38870-38876.
9. Smith SJ, Cases S, Jensen DR, et al. Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat1. Nat Genet 2000; 25: 87-90.
10. Chen HC, Farese RV Jr,. Inhibition of triglyceride synthesis as a treatment strategy for obesity: lessons from DGAT-1 deficient mice. Arterioscler Thromb Vasc Biol 2005; 25: 482-486.
11. Buhman KK, Smith SJ, Stone SJ, et al. DGAT1 is not essential for intestinal triacylglycerol absorption or chylomicron synthesis. J Biol Chem 2002; 277: 25474-25479.
12. -/- mice. J Lipid Res 2010; 51: 1770-1780.
13. Okawa M, Fujii K, Ohbuchi K, et al. Role of MGAT2 and DGAT1 in the release of gut peptides after triglyceride ingestion. Biochem Biophys Res Commun 2009; 390: 377-381.
14. Birch AM, Birtles S, Buckett LK, et al. Discovery of a potent, selective, and orally efficacious pyrimidinooxazinyl bicyclooctaneacetic acid diacylglycerol acyltransferase-1 inhibitors. J Med Chem 2009; 52: 1558-1568.
15. Birch AM, Buckett LK, Turnbull AV,. DGAT1 inhibitors as anti-obesity and anti-diabetic agents. Curr Opin Drug Discov Dev 2010; 13: 489-496.
16. Fox BM, Iio K, Li K, et al. Discovery of pyrrolopyridazines as novel DGAT1 inhibitors. Bioorg Med Chem Lett 2010; 20: 6030-6033.
17. King AJ, Segreti JA, Larson KJ, et al. In vivo efficacy of acyl CoA: Diacylglycerol acyltransferase (DGAT) 1 inhibition in rodent models of postprandial hyperlipidemia. Eur J Pharmacol 2010; 637: 155-161.
18. Yamamoto T, Yamaguchi H, Miki H, et al. Coenzyme A: diacylglycerol acyltransferase 1 inhibitor ameliorates obesity, liver steatosis, and lipid metabolism abnormality in KKAy mice fed high-fat or high-carbohydrate diets. Eur J Pharmacol 2010; 640: 243-249.
19. King AJ, Judd AS, Souers AJ,. Inhibitors of diacylglycerol transferase: a review of 2008 patents. Expert Opin Ther Pat 2010; 20: 19-29.
20. Schober G, Arnold M, Birtles S, Buckett L, Turnbull AV, Langhans W,. DGAT-1 inhibition increases plasma glucagon-like peptide-1 (GLP-1) and peptide tyrosine-tyrosine (PYY) levels in response to a high fat (HF) meal in rats. Appetite 2011; 57: S39.
21. McLaren DG, He T, Wang S-P, et al. The use of stable-isotopically labeled oleic acid to interrogate lipid assembly in vivo: assessing pharmacological effects in preclinical species. J Lipid Res 2011; 52: 1150-1161.
22. O'Donovan D, Feinle-Bisset C, Wishart J, Horowitz M,. Lipase inhibition attenuates the acute inhibitory effects of oral fat on food intake in healthy subjects. Br J Nutr 2003; 90: 849-852.
23. Mortensen K, Christensen LL, Holst JJ, Orskof C,. GLP-1 and GIP are colocalized in a subset of endocrine cells in the small intestine. Regul Pept 2003; 114: 189-196.
24. Liu L, Yu S, Khan RS, et al. DGAT1 deficiency decreases PPAR expression and does not lead to lipotoxicity in cardiac and skeletal muscle. J Lipid Res 2011; 52: 732-744.
25. Streeper RS, Koliwad SK, Villanueva CJ, Farese RV,. Effects of DGAT1 deficiency on energy and glucose metabolism are independent of adiponectin. Am J Physiol Endocrinol Metab 2006; 291: E388-E394.
26. Chen HC, Smith SJ, Ladha Z, et al. Increased insulin and leptin sensitivity in mice lacking acyl CoA: diacylglycerol acyltransferase. J. Clin Invest 2002; 109: 1049-1055.
27. Chen HC, Jensen DR, Myers HM, Eckel RH, Farese RV Jr,. Obesity resistance and enhanced glucose metabolism in mice transplantation with white adipose tissue lacking acyl CoA: diacylglycerol acyltransferase 1. J Clin Invest 2003; 111: 1715-1722.
28. Oh DY, Talukdar S, Bae EJ, et al. GPR 120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010; 142: 687-698.
29. Cox HM, Tough IR, Woolston A-M, Zhang L, Nguyen AD, Sainsbury A,. Peptide YY is critical for acyl ethanolamine receptor Gpr-119-induced activation of gastrointestinal mucosal responses. Cell Metab 2010; 11: 532-542.
30. Ellrichmann M, Kapelle M, Ritter PR, et al. Orlistat inhibition of intestinal lipase acutely increase appetite and attenuates postprandial glucagon-like peptide-1-(7-36)-amide-1, cholecystokinin and peptide YY concentrations. J Clin Endocrinol Metab 2008; 93: 3995-3998.
31. Erion DM, Shulman GI,. Diacylglycerol-mediated insulin resistance. Nat Med 2010; 16: 400-402.
32. Carraso S, Merido I,. Diacylglycerol, when simplicity becomes complex. Trends Biochem Ser 2007; 32: 27-36.